Snake Bite Clinical Trial
Official title:
A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus
In northern Vietnam, a vast majority of the most severe envenomed patients are bitten by Bungarus multicinctus. Hitherto, these victims have received supportive care only. The aims of this study were to assess the possible efficacy and side effects of a newly produced antivenom.
Venomous snakebites constitute a serious health problem in many Asian countries. In Vietnam,
the burden of snakebite on the public health stimulated Calmette to conduct original studies
at the Vaccine Institute in Saigon over a hundred years ago and to develop the first snake
antivenom ever.
In northern Vietnam, a vast majority of the most severe envenomed patients are bitten by
Bungarus multicinctus, which is the only krait species giving rise to significant morbidity
and mortality in the area. Its venom contains toxins which can cause severe neuromuscular
blockade but which do not give rise to swelling or necrosis at the site of the bite.
Supportive care is an important part of the management of snakebites, but antivenom
administration is the mainstay therapy in the majority of medically significant envenomings.
Such specific therapy may dramatically reduce the consequences of the envenomation. In
Vietnam, no specific antivenom against B. multicinctus has been available until recently
when it has produced for clinical use.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00636116 -
Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.
|
Phase 3 | |
| Completed |
NCT00804011 -
Automatic Tube Compensation (ATC) for Weaning Patients With Severe Neurotoxic Snake Envenoming
|
N/A | |
| Terminated |
NCT00639951 -
Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation
|
Phase 4 | |
| Completed |
NCT00868309 -
A Comparison of Crotalinae (Pit Viper) Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab, Ovine Antivenom (CroFab) in the Treatment of Pit Viper Envenomation
|
Phase 2 | |
| Completed |
NCT01284855 -
Comparison of Two Dose Regimens of Snake Antivenom for the Treatment of Snake Bites Envenoming in Nepal
|
Phase 2 |